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 CURRENTOPINION Mendelian randomization to assess causal effects
of blood lipids on coronary heart disease: lessons
from the past and applications to the future
Stephen Burgess and Eric Harshfield
Purpose of review
Mendelian randomization is a technique for judging the causal impact of a risk factor on an outcome from
observational data using genetic variants. Although evidence from Mendelian randomization for the effects
of major lipids and lipoproteins on coronary heart disease (CHD) risk has been around for a relatively long
time, new data resources and new methodological approaches have given fresh insight into these
relationships. The lessons from these analyses are likely to be highly relevant when it comes to lipidomics
and the analyses of lipid subspecies whose biology is less well understood.
Recent findings
Although analyses of low-density lipoprotein cholesterol and lipoprotein(a) are unambiguous as there are
genetic variants that associate exclusively with these risk factors and have well understood biology,
analyses for triglycerides, and high-density lipoprotein cholesterol (HDL-c) are less clear. For example, a
subset of genetic variants having specific associations with HDL-c are not associated with CHD risk, but an
allele score including all variants associated with HDL-c does associate with CHD risk. Recently developed
methods, such as multivariable Mendelian randomization, Mendelian randomization-Egger, and a
weighted median method, suggest that the relationship between HDL-c and CHD risk is null, thus confirming
experimental evidence.
Summary
Robust methods for Mendelian randomization have important utility for understanding the causal
relationships between major lipids and CHD risk, and are likely to play an important role in judging the
causal relevance of lipid subspecies and other metabolites measured on high-dimensional phenotyping
platforms.
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INTRODUCTION
Mendelian randomization is the use of genetic var-
iants as proxies for increased or decreased exposure
to a modifiable phenotype (hereafter referred to as a
risk factor) to help judge whether clinical or phar-
maceutical interventions on the risk factor are likely
to lead to changes in a disease outcome [1,2
&
]. The
most straightforward application of Mendelian
randomization involves taking a single genetic var-
iant that is associated with the risk factor, but not
associated with other risk factors that may represent
confounders or alternative causal pathways to the
outcome [3]. Such a genetic variant may be hard to
find, but for protein biomarkers such as fibrinogen
or C-reactive protein, genetic variants in or near the
relevant coding region (in these cases, the FGB and
CRP gene regions, respectively [4,5]) have been
shown to have good specificity of association with
the risk factor, at least for measured confounders. An
association between such a genetic variant and the
outcome is indicative of a causal effect of the risk
factor on the outcome [6]. In other cases, such as for
IL-1 [7], genetic variants may be associated with
alternative risk factors (in this case, C-reactive
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protein and IL-6), but so long as these risk factors
represent a single causal pathway (i.e., they are up or
downstream of the target risk factor and there is no
alternative causal pathway from the genetic variants
to the outcome that does not go via the target risk
factor), the assumptions necessary for Mendelian
randomization would not be violated [8].
Under furtherparametricassumptions (including
linearity), an estimate of the causal effect of the risk
factor on the outcome can be obtained [9]. The causal
estimate from Mendelian randomization is likely to
differ from the impact of intervening on the risk
factor in practice for many reasons (e.g., the genetic
effect is lifelong) [10]. Hence the magnitude of the
causal estimate should not be taken too literally, but
the causal estimate is a valid test statistic for testing
the causal null hypothesis. This enables information
on multiple genetic variants to be combined into a
single causal estimate, which has greater power to
detect a causal effect than a test of the association of
any of the individual genetic variants with the out-
come [11]. One recent innovation is the use of sum-
marized data on genetic associations with the risk
factor and with the outcome to obtain a causal esti-
mate [12,13]. These associations can come from a
single dataset (one-sample setting), or from separate
datasets (two-sample setting) [14]. A practical
advantage of the use of summarized data is the ability
to analyse publicly available data from large consortia
[15] – such as the Global Lipids Genetics Consortium
[16], who have made associations of genetic variants
with low-density lipoprotein cholesterol (LDL-c),
high-density lipoprotein cholesterol (HDL-c),
and triglycerides in over 188 000 individuals available
(http://www.sph.umich.edu/csg/abecasis/public/lip-
ids2013/), and CARDIoGRAMplusC4D [17], who
have made associations with coronary heart disease
(CHD) risk available in over 60 000 cases and 125 000
controls (http://www.cardiogramplusc4 d.org/down-
loads/). These methods and data resources (in particu-
lar, the large sample sizes of consortium data and the
ease of obtaining genetic association estimates) have
revolutionized the practice and power of Mendelian
randomization investigations [18].
In this review, we first consider Mendelian
randomization analyses of major lipids and lipopro-
teins – LDL-c, HDL-c, triglycerides, and lipopro-
tein(a) – on CHD risk. We discuss methodological
innovations in Mendelian randomization (motiv-
ated in part by these analyses), and their application
to the assessment of the causal effects of these lipids
on CHD risk. Finally, we explore the impact of
technological advances, such as differentiating
major lipids into lipid subspecies using high-dimen-
sional phenotyping platforms, and the potential
utility of these advances in a Mendelian randomiz-
ation framework.
MENDELIAN RANDOMIZATION ANALYSES
OF MAJOR LIPIDS AND LIPOPROTEINS ON
CORONARY HEART DISEASE RISK
Genetic evidence for a link between hypercholester-
olemia and CHD risk has a long history [19] that
precedes the popularization of Mendelian randomiz-
ation. Links between LDL-c and CHD risk are well
established for both common and rare genetic var-
iants [20], and formal approaches for Mendelian
randomization have clearly shown a deleterious
causal effect of increased LDL-c on CHD risk
[21,22]. In many ways, LDL-c is an ideal risk factor
for use in Mendelian randomization. Several genetic
variants associated with LDL-c are located in gene
regions that also have corresponding pharmaceutical
interventions, such as the HMGCR gene region for
statins [23], and the PCSK9 gene region for proprotein
convertase subtilisin/kexin type 9-inhibitors [24,25].
Indeed, a Mendelian randomization analysis using
variants in the NPC1L1 gene region [26
&&
] was pub-
lished in advance of a large trial of ezetimibe (a
Niemann-Pick C1-Like 1-inhibitor) [27], and cor-
rectly predicted its result. The possible benefit of
combination therapy by statin and ezetimibe has
been considered in a factorial Mendelian randomiz-
ation analysis, comparing individuals with geneti-
cally lowered LDL-c because of HMGCR variants
alone, because of NPC1L1 variants alone, and because
of the presence of variants in both gene regions [28].
Genetic variants in different gene regions, as well as
genetic variants with varying strengths of association
KEY POINTS
 Mendelian randomization is a technique to determine
the causal impact of a risk factor on an outcome from
observational data using genetic variants.
 Robust methods for Mendelian randomization have
important utility for understanding the causal
relationships between major lipids and CHD risk.
 Multivariable Mendelian randomization, Mendelian
randomization-Egger, and a weighted median method
for Mendelian randomization are important recently
developed methods that are likely to play an important
role in judging the causal relevance of lipid subspecies
and other metabolites measured on high-dimensional
phenotyping platforms.
 There is tremendous scope and untapped potential to
apply Mendelian randomization in investigating
plausible novel causal pathways of high-dimensional
phenotypic traits with diseases and risk factors.
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with LDL-c concentrations (including rare gain-of-
function and loss-of-function mutations with large
effects on LDL-c) have been shown to have associ-
ations with CHD risk that are proportional to their
association with LDL-c [29], both strengthening the
argument that LDL-c is the relevant causal risk factor,
and suggesting that all mechanisms of LDL-c-low-
ering seem to have similar effects on CHD risk. How-
ever, the magnitude of the genetically-predicted
causal effect of LDL-c on CHD risk is much larger
than the observed reduction in CHD risk from taking
statins; the Mendelian randomization estimate is 3.5
times larger than the estimate from trials [10] (based
on taking statins for 5þ years in primary prevention
[30]). One explanation for this is that genetically
predicted variation in LDL-c concentrations is life-
long, and so the Mendelian randomization estimate
represents the effect of long-term reduction in LDL-c.
Genetic studies have corroborated the slight increases
in type 2 diabetes (T2D) risk that are observed in statin
trials [31], with several LDL-c-lowering variants show-
ing suggestive associations with increased T2D risk
[32
&
]. This suggests that the increase in T2D risk is
likely to be an on-target effect of statin drugs, rather
than an off-target effect; also that it may be a con-
sequence of LDL-c-lowering more widely rather than
a specific effect of intervention on the 3-hydroxy-
3-methylglutaryl-CoA reductase pathway.
A similar story can be told for lipoprotein(a). The
kringle IV type 2 size polymorphism (a copy number
variant) is highly predictive of lipoprotein(a) con-
centrations, explaining 21% of variation in lipopro-
tein(a) [33]. In contrast, no genetic variant for LDL-
c, HDL-c, or triglycerides explains more than 1% of
variation [16]. This polymorphism (and also single
nucleotide polymorphisms in the LPA region [34])
are also associated with CHD risk, suggesting a
deleterious causal effect of increased lipoprotein(a)
on CHD risk [33]. Similarly to that for LDL-c, the
effect estimate from the Mendelian randomization
analysis is 2.5 times greater than that from a stand-
ard observational analysis [33]. Another explanation
for this, which may also be relevant to other Men-
delian randomization analyses, is that genetic var-
iants may be associated with another aspect of lipid
biology (such as particle size or activity) and not
just concentration.
For triglycerides, the story is less clear because of
a lack of genetic variants associated with triglycer-
ides that do not also associate with LDL-c and/or
HDL-c. A methodological development to address
this is multivariable Mendelian randomization, in
which the causal effects of multiple risk factors can
be estimated simultaneously [35
&
]. This requires
genetic variants to be associated with one or more
of the risk factors, but not associated with other risk
factors that may represent confounders of any risk
factor – outcome association or alternative causal
pathways to the outcome that are not via one of the
target risk factors. Multivariable Mendelian random-
ization analyses have suggested a deleterious causal
effect of increased triglycerides on CHD risk [36,37].
However, there is little consistency in the associ-
ations of individual triglyceride-related variants
with CHD risk [38], with some variants being associ-
ated with CHD risk [39,40], and others showing no
clear association. This may reflect genuine hetero-
geneity among different triglycerides.
Although there are genetic variants that appear
to have specific associations with HDL-c, these var-
iants are not associated with CHD risk [41]. How-
ever, an allele score based on all the genetic variants
known to be associated with HDL-c at a genome-
wide level of significance is associated with CHD
risk, suggesting a protective causal effect of HDL-c
(if the Mendelian randomization assumptions are
satisfied – see later) [42
&
]. Holmes et al. demon-
strated an inverse association with CHD risk for
an unrestricted score that explained 3.8% of the
variance in HDL-c, but no association for a restricted
score omitting variants additionally associated with
LDL-c or triglycerides that explained 0.3% of the
variance in HDL-c. One explanation for the null
finding with the restricted score is that the analysis
lacked the power to detect a causal effect. Multi-
variable Mendelian randomization is a useful tool in
this case, as a multivariable analysis can include
genetic variants that have pleiotropic associations
with either LDL-c or triglycerides. This provides
robustness to pleiotropy but still reasonable power
to detect a causal effect. A multivariable Mendelian
randomization analysis using a limited number of
genetic variants did not reveal a causal effect of
HDL-c [35
&
], and neither did an initial analysis,
including all genome-wide significant variants
[36]. Although a more principled multivariable
Mendelian randomization analysis taking into
account the relative weights of the genetic variants
did suggest a protective effect of HDL-c [37], the
magnitude of the effect was much smaller (4.5 times
smaller) than that for LDL-c; there is also the poten-
tial of some residual bias because of pleiotropic




RANDOMIZATION ANALYSIS OF MAJOR
LIPIDS
Two other methodological advances that have
relevance to assessing the causal relevances of major
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lipids are: Mendelian randomization-Egger [43
&&
]
and a weighted median method [44
&&
]. Mendelian
randomization-Egger is a method adapted from the
meta-analysis literature on publication bias [45]. In a
Mendelian randomization setting, each genetic var-
iant contributes an estimate of the causal effect, and a
pooled estimate is calculated based on all the genetic
variants (genetic variants are treated similarly to
studies in a meta-analysis). However, if even one of
the genetic variants violates the Mendelian random-
ization assumptions, then the causal estimate from
that variant will be biased, and the usual pooled
estimate (known as the inverse-variance weighted
estimate [13]) will be biased and have an inflated type
1 error rate. This may lead to false positive findings
when genetic variants are pleiotropic [46]. Rather
than the standard approach, which assesses whether
genetic variants associated with the risk factor are also
associated with the outcome, Mendelian randomiz-
ation-Egger assesses whether there is a dose-response
relationship in the genetic associations with the risk
factor and with the outcome. This is a higher standard
of proof than demanded in a standard Mendelian
randomization analysis, and so Mendelian random-
ization-Egger has reduced type 1 error rates [43
&&
].
Mendelian randomization-Egger enables a test of
‘directional pleiotropy’ (whether pleiotropic associ-
ations of genetic variants are likely to bias causal
estimates in one particular direction). Additionally,
under the assumption that genetic variants may have
pleiotropic effects on the outcome, but that these
pleiotropic effects are uncorrelated with instrument
strength [47], Mendelian randomization-Egger pro-
vides a consistent estimate of the causal effect [43
&&
].
The weighted median method is a simple idea:
rather than taking a pooled estimate that is a
weighted mean of the causal estimates based on
each genetic variant individually, to report a pooled
estimate that is a weighted median [48]. The median
is not affected by outlying results, and so the
weighted median estimate is not sensitive to a hand-
ful of pleiotropic genetic variants. Formally, it is a
consistent estimate of the causal effect if at least half
of the genetic variants (by weight) are valid instru-
ments [44
&&
]. Both approaches are worthwhile sen-
sitivity analyses for Mendelian randomization when
some genetic variants are suspected to be pleio-
tropic. The Mendelian randomization-Egger esti-
mate has the advantage that it allows all genetic
variants to be pleiotropic, although it makes an
assumption on the distribution of these pleiotropic
effects; however, it may be imprecise, and it is highly
influenced if there are one or two strong variants.
The weighted median estimate is more precise and
more stable, but relies on the majority of evidence in
the analysis being reliable.
The application of these methods to major lipids
is very revealing: using all genome-wide significant
variants, all analyses (standard Mendelian random-
ization, Mendelian randomization-Egger, weighted
median) suggest causal effects of LDL-c and
triglycerides on CHD risk, with no evidence of direc-
tional pleiotropy [44
&&
]. However, although the
standard Mendelian randomization analysis using
all genome-wide significant variants for HDL-c
suggests a protective effect of HDL-c on CHD risk,
the Mendelian randomization-Egger and weighted
median analyses suggest a null effect, with evidence
of directional pleiotropy in the Mendelian random-
ization-Egger analysis [44
&&
]. This null finding is
supported by trial evidence on cholesteryl ester
transfer protein inhibitors, which raise HDL-c levels,
but do not lower CHD incidence [49].
The conclusion from this is that Mendelian
randomization analyses can besimpleor not,depend-
ing on the available genetic variants and their speci-
ficityofassociationwith the risk factorunderanalysis.
A naive Mendelian randomization analysis, particu-
larly one using a large number of genetic variants, can
be misleading. However, the development of new
methods can help either to add confidence in the
finding from a Mendelian randomization analysis, or
to call it into question [50
&
].
FUTURE DIRECTIONS FOR MENDELIAN
RANDOMIZATION
High-throughput phenotyping approaches to
collecting ‘omics’ data, including genomics, tran-
scriptomics, metabolomics, and proteomics, have
recently been gaining traction; new approaches
are constantly being developed to measure an
ever-widening number of phenotypic traits on
larger and larger populations. The measurement
of such a vast array of high-dimensional phenotypic
traits brings novel opportunities to perform
genome-wide association studies (GWAS) that can
examine the associations of millions of genetic var-
iants with thousands of metabolites or proteins
[51
&&
]. Lipidomics is a subset of metabolomics con-
cerned with the study of lipid profiles derived from
mass spectrometry or NMR platforms, which pro-
duces information on the composition and abun-
dance of lipids in the body, thereby contributing to
an understanding of how lipids function in a bio-
logical system [52]. Although numerous metabolo-
mics GWAS have been performed in recent years
[53
&&
], very few high-dimensional phenotyping
studies have used a Mendelian randomization
approach to assess whether the associated pheno-
typic traits that they identified could have causal
effects on diseases or risk factors.
Mendelian randomization of blood lipids Burgess and Harshfield
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The studies that have employed Mendelian
randomization on high-throughput data have taken
either of two approaches: to determine the causal
role of conventional risk factors on levels of high-
dimensional phenotypes (e.g., metabolites), or to
determine whether high-dimensional phenotypes
have a causal effect on diseases or traits. As an
example of the first approach, a meta-analysis of
four Finnish population cohorts obtained levels of
82 different metabolites and metabolic measures
using nuclear magnetic resonance, including lipo-
protein lipids, fatty acids, and amino acids [54]. The
authors found evidence that strongly supports
causal effects of adiposity on 24 metabolites that
are potential cardiometabolic risk factors [54].
Another study using mass spectrometry in a British
population determined that gene expression levels
derived from expression quantitative trait loci in fat,
skin, and lymphoblastoid cell lines could play a
causal role on levels of a wide range of metabolites
[55]. The authors identified two loci (THEM4 and
CYP3A5) where the allele associated with increased
metabolite levels was significantly associated with
decreased gene expression in one or more tissues,
supporting the notion that the underlying causal
variants at these two loci could have regulatory
consequences [55]. To illustrate the second
approach, a prospective cohort study that con-
ducted mass spectrometry used summarized CHD
association results from CARDIoGRAMplusC4D to
find four lipid-related metabolites (lysophosphati-
dylcholines 18 : 1 and 18 : 2, monoglyceride 18 : 2,
and sphingomyelin 28 : 1) with evidence for a causal
role in CHD development [56
&
].
Metabolomics and proteomics particularly
stand to benefit from the availability of summarized
data for Mendelian randomization and a two-
sample setting, where the associations of high-
dimensional phenotypic traits with genetic variants
are measured in one population (usually a small
cross-sectional study of healthy individuals) and
the associations of those variants with diseases
and risk factors are measured in another population,
such as the large consortia mentioned earlier (for
disease outcomes, usually a consortium of case-con-
trol studies) [15]. Furthermore, the multivariable
Mendelian randomization approach will be particu-
larly relevant to high-dimensional platforms, as it
may be difficult to find genetic variants having a
specific association with a single variable (and in
lipidomics in particular [57]). However, it is import-
ant to distinguish between pleiotropy and media-
tion (also called ‘horizontal’ and ‘vertical’
pleiotropy) [15]: if several metabolites are on the
same causal pathway, then a genetic variant associ-
ated with all of these metabolites is not truly
pleiotropic, as the associations reflect a single causal
pathway. In this case, a Mendelian randomization
analysis can assess the causal effect of the entire
pathway, but it cannot address the question of
causation for any of the individual metabolites on
the pathway without incorporating additional bio-
logical information. The particular challenge of
Mendelian randomization with high-dimensional
assays lies in identifying a suitable set of genetic
variants for a particular metabolite or protein
(or a small set of metabolites or proteins for multi-
variable Mendelian randomization) that will not
violate Mendelian randomization assumptions.
Thus, the Mendelian randomization-Egger and
weighted median methods could be especially
important to provide some robustness against plei-
otropic variants.
CONCLUSION
There is tremendous scope and untapped potential
to apply Mendelian randomization in investigating
plausible novel causal pathways of high-dimen-
sional phenotypic traits with diseases and risk fac-
tors. Mendelian randomization is a tool that can
provide additional evidence to prioritize further
research and clinical applications, or just as impor-
tantly, to discourage additional resource allocation
toward a specific pathway. Over the next few years,
Mendelian randomization is likely to be applied
with increasing regularity to high-dimensional phe-
notypic data where concomitant genetic infor-
mation is available, and in lipidomics in particular.
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